Elutia (NASDAQ:ELUT) Issues Earnings Results, Misses Estimates By $0.02 EPS

Elutia (NASDAQ:ELUT) issued its quarterly earnings data on Thursday. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02), FiscalAI reports. The company had revenue of $2.43 million for the quarter, compared to analyst estimates of $2.90 million.

Here are the key takeaways from Elutia’s conference call:

• Positive Sentiment: Elutia secured up to $26 million in additional non-equity capital, including a $15 million Avenue Capital credit facility and proceeds from the planned SimpliDerm sale. Management believes total projected cash sources of up to $54 million provide runway through the anticipated NXT-41x launch in 2028.
• Positive Sentiment: An independent blinded survey of 50 reconstructive surgeons found strong potential demand for NXT-41x: 96% expressed interest in using it, 100% would use it for high-risk patients, and 92% would champion it before their hospital’s value analysis committee.
• Positive Sentiment: Management reiterated that NXT-41 is expected to receive an FDA clearance decision in the fourth quarter of 2026, while NXT-41x remains targeted for clearance in the first half of 2027. Commercial manufacturing qualification is complete, with initial production capacity expected to support at least $300 million in annual revenue.
• Negative Sentiment: Second-quarter net sales declined to $2.4 million from $2.7 million, primarily because of a contract-manufacturer disruption affecting SimpliDerm. Continuing-operations net loss widened to $7.6 million from $7.1 million, and adjusted EBITDA loss increased to $4.6 million from $3.0 million as R&D spending rose.
• Neutral Sentiment: Elutia is narrowing its focus to NXT-41x by selling SimpliDerm and continuing a strategic process for its cardiovascular business. While this should reduce commercial expenses and concentrate resources, the transactions remain subject to closing and could temporarily leave the company without a commercial product before NXT-41x launches.

Elutia Stock Performance

Shares of ELUT stock traded up $0.04 during mid-day trading on Thursday, reaching $0.86. 122,257 shares of the stock traded hands, compared to its average volume of 94,402. The stock’s fifty day simple moving average is $0.94 and its two-hundred day simple moving average is $1.03. Elutia has a 1-year low of $0.50 and a 1-year high of $2.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Deerfield Management Company L.P. bought a new position in Elutia in the 3rd quarter valued at approximately $1,221,000. XTX Topco Ltd bought a new stake in Elutia during the 4th quarter worth approximately $71,000. Renaissance Technologies LLC increased its position in Elutia by 64.7% in the 4th quarter. Renaissance Technologies LLC now owns 102,116 shares of the company’s stock valued at $71,000 after acquiring an additional 40,123 shares during the period. Citadel Advisors LLC acquired a new position in Elutia in the 3rd quarter valued at approximately $50,000. Finally, Virtu Financial LLC bought a new position in shares of Elutia during the third quarter valued at $26,000. Institutional investors and hedge funds own 74.03% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Elutia from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 23rd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Elutia presently has an average rating of “Hold” and a consensus price target of $6.00.

Elutia Company Profile

Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.

The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.